Revenue: As of FY2026 Q1, the actual value is USD 823.4 M.EPS: As of FY2026 Q1, the actual value is USD 0.02.<h4>Total Company Performance</h4>BRUKER CORPORATION reported total revenues of $823.4 million for Q1 2026, an increase of 2.7% year-over-year, but a decrease of 4.4% organically, including 2.6% growth from acquisitions and a 4.5% favorable impact from foreign currency translation . GAAP Operating Income was $10.2 million in Q1 2026, down from $31.8 million in Q1 2025 . Non-GAAP Operating Income was $84.2 million in Q1 2026, compared to $101.7 million in Q1 2025 . The Non-GAAP Operating Margin was 10.2% in Q1 2026, a decrease from 12.7% in Q1 2025 . GAAP Gross Profit was $379.8 million in Q1 2026, compared to $391.2 million in Q1 2025 . Non-GAAP Gross Profit was $411.8 million in Q1 2026, compared to $410.9 million in Q1 2025 . GAAP Gross Profit Margin was 46.1% in Q1 2026, down from 48.8% in Q1 2025 . Non-GAAP Gross Profit Margin was 50.0% in Q1 2026, compared to 51.3% in Q1 2025 .<h4>Operating Costs</h4>Selling, General and Administrative (GAAP) expenses were $242.1 million in Q1 2026, up from $225.4 million in Q1 2025 . Research and Development (GAAP) expenses increased to $101.3 million in Q1 2026 from $97.1 million in Q1 2025 . Other Charges, Net (GAAP) were $26.2 million in Q1 2026, a decrease from $36.9 million in Q1 2025 . Total Operating Expenses (GAAP) for Q1 2026 were $369.6 million, up from $359.4 million in Q1 2025 .<h4>Segment Revenue</h4>Bruker Scientific Instruments (BSI) revenue was $759.8 million, an increase of 2.1% year-over-year, but a decrease of 5.0% organically . Within BSI, Bruker BioSpin revenue was $197.5 million in Q1 2026, compared to $207.8 million in Q1 2025 . Bruker CALID revenue was $316.3 million in Q1 2026, up from $280.1 million in Q1 2025 . Bruker Nano revenue was $246.0 million in Q1 2026, compared to $256.6 million in Q1 2025 . Bruker Energy &amp; Supercon Technologies (BEST) revenue was $66.9 million, marking a 12.8% year-over-year increase and a 3.0% organic increase . Eliminations were -$3.3 million in Q1 2026, compared to -$2.4 million in Q1 2025 .<h4>Operational Metrics</h4>BSI Bookings increased organically by high-single digits percentage year-over-year in Q1 2026 . The BSI Book-to-Bill Ratio was above 1.0x for the third consecutive quarter . Bookings trends included solid academic orders for post-genomic research solutions from outside the US, strong AI-driven demand in semiconductor metrology and SciY laboratory software, and strength in industrial research tools and security detection systems .<h4>Cash Flow</h4>Net Cash Provided by Operating Activities was $71.2 million in Q1 2026, up from $65.0 million in Q1 2025 . Purchases of Property, Plant and Equipment were -$24.2 million in Q1 2026, compared to -$26.0 million in Q1 2025 . Non-GAAP Free Cash Flow was $47.0 million in Q1 2026, compared to $39.0 million in Q1 2025 . Cash and Cash Equivalents stood at $133.4 million as of March 31, 2026, down from $298.8 million as of December 31, 2025 .<h4>Fiscal Year 2026 Financial Outlook</h4>BRUKER CORPORATION reconfirmed its FY2026 guidance, expecting revenues of $3.57 billion to $3.60 billion, representing 4% to 5% year-over-year growth, with organic growth projected at 1% to 2% . The company anticipates a return to organic revenue growth in Q2 and expects to deliver significant operating margin expansion and double-digit EPS growth for the full fiscal year . Non-GAAP EPS is forecasted to be between $2.10 and $2.15, an increase of 15% to 17% year-over-year, despite an approximately 8% foreign exchange headwind .

Bruker Corp Pref Shares BRKRP 6.375 09/01/2028 | 8-K: FY2026 Q1 Revenue: USD 823.4 M